

Attorney's Docket No. 5800-8A (35800/185816)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1646 \$
RECEIVED

In re: Glucksmann *et al.*

Confirmation No.:

Appl. No.: 09/383,745

Group Art Unit: 1646

Filed: August 26, 1999

Examiner: E. Lazar-Wesley

For: 14926 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR

OCT 12 2001
TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231



October 3, 2001

Sir:

Transmitted herewith is an AMENDMENT in the above-identified patent application.

- ☐ Applicant claims small entity status. See 37 C.F.R. § 1.27.
☐ No additional fee is required.

The fee has been calculated as shown below:

(COL. 1)		(COL. 2)	(COL. 3)	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	OR RATE	ADDIT. FEE
TOTAL	* 28	** 27	= 1	X9=	\$	X18=	\$ 18
INDEP	* 8	*** 3	= 5	X42=	\$	X84=	\$ 420
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				+140=	\$	+280=	\$
				TOTAL ADD FEE \$		OR TOTAL	\$ 438

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior Amendment or the number of claims originally filed.

In re: Glucksmann et al.
Appl. No.: 09/383,745
Filed: August 26, 1999
Atty. Dock. No. 5800-8A (35800/185816)
Page 2

- ☐ Please charge my Deposit Account No. 16-0605 in the amount of \$.
- ☒ A check in the amount \$438 to cover the additional fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge any deficiency in payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-0605.
- ☒ Any additional filing fees required under 37 C.F.R. § 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 C.F.R. § 1.17.

Respectfully submitted,

Kathryn L. Coulter

Kathryn L. Coulter
Registration No. 45,889
Agent of Record

CUSTOMER NO. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

**CERTIFICATION OF FACSIMILE
TRANSMISSION**

I hereby certify that this paper is being facsimile
transmitted to the Patent and Trademark Office at Fax No.
on the date shown below.

(Type or print name of person signing certification.)

Signature


Date

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being
deposited with the United States Postal Service with
sufficient postage as first class mail in an envelope
addressed to: Commissioner for Patents, Washington, DC
20231, on October 3, 2001.

Wendy Wagner
Wendy Wagner

Attorney's Docket No. 5800-8A (35800/185816)



#12/B
#120115
RECEIVED

OCT 12 2001

TECH CENTER 1600/2900
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Glucksmann *et al.*

Appl. No.: 09/383,745

Filed: August 26, 1999

For: 14926 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR

Confirmation No.:

Group Art Unit: 1646

Examiner: E. Lazar-Wesley

October 3, 2001

Commissioner for Patents
Washington, DC 20231

AMENDMENT

Sir:

In response to the Office Action mailed July 3, 2001, please amend the above-identified application as follows:

In the Specification:

Please delete the paragraph on lines 6-11 of page 10.

Please amend the paragraph on lines 10-13 of page 4 to read as follows:

B₁ The invention provides isolated 14926 receptor polypeptides including a polypeptide having the amino acid sequence shown in SEQ ID NO:1.

Please amend the paragraph on lines 14-15 of page 4 to read as follows:

B₂ The invention also provides isolated 14926 receptor nucleic acid molecules having the sequence shown in SEQ ID NO:2.

Please amend the paragraph on lines 16-18 of page 4 to read as follows:

B₃ The invention also provides variant nucleic acid sequences that are substantially homologous to the nucleotide sequence shown in SEQ ID NO:2.

10/11/2001 AOSMAN1 00000015 09383745

01 FC:102
02 FC:103

420.00 OP
18.00 OP

RTA01/2104041v1